Zivo Bioscience, Inc.
ZIVO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001101026
No open-market purchases or sales by Zivo Bioscience, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17.6K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Zivo Bioscience, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q4 2022
- Shares held
- 438.6K
- +9.04K (+2.1%) vs. Q4 2022
- Total value
- $1.35M
- +$285.3K (+26.9%) vs. Q4 2022
- New holders
- 1
- 4 more added
- Sold out
- 1
- 1 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZIVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $17.6K |
| Q1 2026 | 2 | $30.1K |
| Q4 2025 | 3 | $43.2K |
| Q3 2025 | 2 | $58.3K |
| Q2 2025 | 2 | $60.4K |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $10.8K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 2 | $216 |
| Q3 2023 | 14 | $1.65M |
| Q2 2023 | 14 | $3.57M |
| Q1 2023 | 14 | $1.35M |
| Q4 2022 | 15 | $1.13M |
| Q3 2022 | 14 | $1.41M |
| Q2 2022 | 13 | $2.08M |
| Q1 2022 | 14 | $2.05M |
| Q4 2021 | 14 | $1.66M |
| Q3 2021 | 12 | $828.6K |
| Q2 2021 | 8 | $194.7K |
| Q1 2021 | 3 | $55.2K |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Zivo Bioscience, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 276,623 | $846.5K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 109,339 | $336.8K | 0.00% | +9,533+9.6% | Added |
| BlackRock Inc. | 15,619 | $48.1K | 0.00% | +510+3.4% | Added |
| Column Capital Advisors, LLC | 12,000 | $37.0K | 0.01% | 00.0% | Unchanged |
| Wells Fargo & Company | 11,316 | $34.9K | 0.00% | +10.0% | Added |
| Verdence Capital Advisors LLC | 10,000 | $30.8K | 0.00% | 00.0% | Unchanged |
| Bartlett & Co. Wealth Management LLC | 1,000 | $3.08K | 0.00% | 00.0% | Unchanged |
| Bartlett & Co. LLC | 1,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 850 | $2.62K | 0.00% | −920−52.0% | Reduced |
| The PNC Financial Services Group, Inc. | 629 | $1.94K | 0.00% | 00.0% | Unchanged |
| Belpointe Asset Management LLC | 95 | $293 | 0.00% | 00.0% | Unchanged |
| Bourgeon Capital Management LLC | 31 | $96 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 28 | $86 | 0.00% | +14+100.0% | Added |
| Tower Research Capital LLC (TRC) | 24 | $0 | 0.00% | +24 | New |
| Morgan Stanley | 0 | $0 | 0.00% | −125−100.0% | Sold out |
| CoreCap Advisors, LLC | – | – | – | – | Not filed |